cyrilzakka/clinical-trials huggingface dataset:
Preschool CGM Use and Glucose Variability in Type 1 Diabetes

The objectives of this clinical study is to evaluate the efficacy continuous glucose monitoring (CGM) use on glucose variability (GV) in preschool children with T1D treated with CSII.

Downloads from CGM and CSII saved in pdf from will be retrospectively reviewed and analysed for all preschool children with type 1 diabetes in Slovenia. Glucose variability and other glycemic parameters will be analyzed separately for periods when CGM was used (CGM and SMBG data) and compared to periods when CGM was not used (SMBG only data).


Eligibility Criteria:
Inclusion Criteria:

1. Subject with Type 1 diabetes (\&gt; 6 months since diagnosis)
2. Insulin infusion pump CSII therapy for at least 3 months
3. Age ≤ 7 years
4. HbA1c at inclusion ≥ 6.5 and \< 10
5. BMI SDS - below the 95th percentile for age

Exclusion Criteria:

1. Concomitant diseases that influence metabolic control
2. Participation in any other interventional study
3. Known or suspected allergy to trial products
Factors Associated With Nonattendance at Scheduled Outpatient Appointments in a University General Hospital

Our objectives were to estimate the prevalence of nonattendance at outpatient offices, to identify the characteristics of appointments for which nonattendance was more likely to occur, and to generate a predictive model that could be applied to each appointment to estimate the probability of nonattendance.

Nonattendance at scheduled appointments at outpatient clinics is a common problem in general medical practice, representing a significant cost to the health care system, and resulting in disruption of daily work planning.Nonattendance at medical appointments has consequences not only for doctors (as it requires a greater use of resources and time), but also for patients, because there may be deterioration in the quality of care, and dissatisfaction associated with delays in obtaining a new appointment.

Previous studies have reported that nonattendance at scheduled appointments is most frequently associated with those patients attending follow-up appointments, generally those assigned to another professional, those with appointments on Fridays, and those with appointments assigned 1 - 2 weeks in advance. Nonattendance was also associated with younger patient age, greater psychological problems, and lower socioeconomic status.Furthermore, in patients with chronic diseases, the nonattendance rate was also reported to be lower. Clinical patient characteristics can be important predictors of nonattendance, but they required high quality electronic health records to predict nonattendance accurately In the United States and Europe, the nonattendance rate is estimated to be between 6.5%-55%; there is little evidence regarding nonattendance in Latin America. Many studies have described the prevalence and impact of nonattendance at scheduled medical appointments, and possible strategies to decrease the nonattendance rate. However, few studies have utilized the characteristics associated with nonattendance for building predictive models, which might better identify those patients who may not attend a scheduled appointment

Eligibility Criteria:
Inclusion Criteria:

* Over 17 years.
* Adults who attended, did not attend and cancelled a scheduled appointment at the Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)

Exclusion Criteria:

* The refusal to register or to the informed consent process.
Perioperative Fluid Therapy from the Perspective of an Anesthesiologist

A survey conducted in 2022 in ,,Medycyna Praktyczna'' magazine, publishing house regarding fluid therapy in hospital wards showed that many recommendations regarding proper fluid therapy have become common practice, but there are still a significant number of practices established over the years that differ significantly from the principles of good clinical practice

In the period August 28, 2021- April 15, 2022, two online surveys were conducted among anesthesiologists in the ,,Practical Medicine'' magazine, asking about the principles they follow when conducting PFT(Perioperative Fluid Therapy).

Eligibility Criteria:
Inclusion Criteria:

* medical physician

Exclusion Criteria:

* no medical physician
A Study of SHR-4375 in Subjects With Solid Tumors

This is an open-label, three-part study to evaluate the safety and efficacy of SHR-4375 for injection in subjects with solid tumors.


Eligibility Criteria:
Inclusion Criteria:

1. The subjects voluntarily joined the study and signed the ICF.
2. Measurable disease, as defined by RECIST v1.1.
3. The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.
4. Life expectancy ≥ 12 weeks.
5. Subjects with cytologically or histologically confirmed advanced solid tumors who have failed or are intolerant to standard therapy, have no standard therapy, or refuse standard therapy.

Exclusion Criteria:

1. Symptomatic, untreated or active central nervous system metastases.
2. With any active autoimmune disease or history of autoimmune disease.
3. Patients with active hepatitis B or hepatitis C.
4. Severe infections prior to initiation of study treatment.
Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study

This pilot study evaluates safety of administration of red blood cell transfusions requested by patients based on their symptoms instead of levels of hemoglobin for the treatment of chronic anemia in patients with blood disorders.

PRIMARY OBJECTIVE:

I. To assess feasibility and safety of red blood cell transfusions at the time subjects requested based on symptomatic anemia.

SECONDARY OBJECTIVES:

I. To define a patient-driven red blood cell transfusion (RBCT) threshold and to compare the median hemoglobin (hgb) at the time subjects request RBCT to the standard threshold of hgb \< 8 g/dL.

II. To compare the number of red blood cell (RBC) units transfused and the frequency of transfusions at the time subjects request RBCT during the study period to the number of RBC units received and frequency using the standard threshold hemoglobin \< 8 g/dL during a comparable period prior to enrollment.

III. To compare the quality of life (QoL) scores when subjects request RBCT to the scores obtained at the time hgb is 8 +/- 0.5 g/dL.

OUTLINE:

Patients undergo RBCT based on their perception and/or the presence of anemia symptoms for up to 6 months.

After completion of study treatment, patients are followed up for 30 days.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with hematological malignancy or marrow failure syndrome such as but not limited to: aplastic anemia, myelodysplastic syndrome or leukemia
* Chronic transfusion-dependent anemia with exposure to at least 5 RBCT
* Interested in reducing transfusion exposure
* Willing to sign informed consent

Exclusion Criteria:

* Recent acute bleeding requiring intervention in less than 24 hours
* Hemoglobin levels \< 6 g/dL
* Acute leukemia receiving induction chemotherapy
* Any patient with known ischemic heart disease, history of congestive heart failure, history of stroke, or cardiac arrhythmia for which the patient requires medication or a medical device
* Oxygen dependent
* Oxygen saturation below 92% on room air
* Receiving erythropoietin stimulating agent
* Thalassemia major or sickle cell disease requiring blood transfusion
* Undergoing major surgery
* Hemolytic anemia
* Coagulopathies including disseminated intravascular coagulation (DIC), receiving anticoagulant or antiplatelet agents
* Diagnosed with chronic obstructive pulmonary disease (COPD) oxygen dependent
* Pregnancy
* Participation in a therapeutic clinical trial
Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™

The purpose of this study is to assess the feasibility of TrueLoo™, an Internet-connected smart toilet seat, in accurately monitoring and logging bowel movements and urinations of residents in senior living facilities across Northern California.

The logging and monitoring of bowel movements and urinary events is an important aspect of preventative care for residents in senior living facilities, providing early warning signs for conditions that may otherwise cause complications if dealt with reactively. However, this information is sporadically collected - if at all - and subjectively interpreted by caregivers, leading to inconsistencies and unreliable data. Toi Labs, Inc. has created TrueLoo™, an Internet-connected toilet seat, as a solution to these issues. TrueLoo™ acquires time-lapse images of a bowel movement or urinary event automatically and under controlled conditions. Residents enrolled in the current study will have a TrueLoo™ installed in their private bathroom, through which all bowel movements and urinary events will be tracked, anonymously, privately, and securely. As a result, an electronic bowel movement and urinary event log for each enrolled resident will be generated. Given sufficient data, the TrueLoo™ system will complete such electronic logs automatically, identify points in time where particular enrolled residents may have experienced anomalous toileting patterns, and determine the relevance of such events through targeted health history and urine sampling.

Eligibility Criteria:
Inclusion Criteria:

* Must be willing to participate and provide consent for the study;
* Must be a male or female, aged 55 or older;
* Must be a resident of a senior living facility;
* Must have regular access to a TrueLoo™.

Exclusion Criteria:

* Candidates who are unwilling or unable to accept the requirements associated with installing TrueLoo™ in their residence, including power and Wi-Fi connectivity;
* Candidates who use certain types of toileting assistance devices that at this time are not compatible with TrueLoo™ (e.g., padded toilet seat risers).
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

APEX is a prospective multi-site registry of real-world experience with the Optilume™ BPH Catheter System for treatment of men experiencing symptomatic BPH.


Eligibility Criteria:
Inclusion Criteria:

1. Patients treated with the Optilume BPH Catheter System in accordance with the Instructions for Use (IFU).

Exclusion Criteria:

1. Unwilling to abstain from sexual intercourse or use a condom for 30 days post-procedure and utilize a highly effective contraceptive for at least 12 months post-procedure
2. Presence of an artificial urinary sphincter, penile prosthesis, or stent(s) in the urethra or prostate
3. Confirmed or suspected malignancy of prostate or bladder.
4. Active urinary tract infection (UTI)
5. Anatomy (e.g., presence of false passage or size of meatus) is not suitable for treatment with the Optilume BPH Catheter System
Phosphorylation of ERK1/2 in Patients With Parkinson's Disease

Levodopa-induced dyskinesia severely limits the use of levodopa in Parkinson's disease and constitutes a debilitating complication of dopaminergic treatment in late stage. Among several neurobiological mechanisms identified so far, the investigators have established in experimental models the key role of D1 receptor hypersensitivity and a"Ras-ERK" signalling pathway. As the very same dopamine receptor machinery and the Ras-ERK pathway are present in blood lymphocytes, the investigators wish to test the hypothesis that the level of ERK phosphorylation in lymphocytes is a biomarker of levodopa-induced dyskinesia in Parkinson's Disease.

The study will be performed in dyskinetic levodopa-treated patients and non-Parkinson's Disease controls. Blood sampling "off" and "on" levodopa treatment (1 hour post-dose), as well as clinical data collection will be done during a scheduled pre-op work-up (deep brain stimulation). Subsequently, suspended lymphocytes from blood samples will be immunolabelled using an anti-pERK antibody and mean fluorescence intensity and percent of labelled lymphocytes will be assessed by flow cytometry. Additionally, plasma and urine samples will be collected "on" et "off" for dosage of dopamine. The motor effect of levodopa will be assessed through UPRSIII rating scale and eye movement (saccades) speed by non-invasive oculometric recordings.


Eligibility Criteria:
Inclusion Criteria:

* Consecutive eligible PD in- and outpatients selected at the university hospital of Bordeaux.
* Non-demented patients (DSM IV) who are able to give their informed consent and who are affiliated to the social security.
* Controls: Subjects without known neurological disorder, non-demented, able to give their informed consent and affiliated to the social security.

Exclusion Criteria:

* Patients: Atypical or secondary parkinson disease.
* Previous or current cancer or malignant haemopathy.
* Known auto-immune disease.
* Anti-neoplastic or immuno-modulator treatment (particularly corticosteroids). Immuno-deficient subjects.
* Acute viral infection (within 2 weeks after resolving). Statin drug intake. Demented subject (DSMIV).
* Controls: Same criteria as above plus any neurological disease.
Trial Comparing Different Medical Devices for Infragenual Dilatation

This study is a comparison of different medical devices for infragenual dilatation.

Dilatation and recanalisation of the distal veins (infragenual popliteal artery, tibiofibular trunc, posterior tibial artery, anterior tibial artery) by classical balloon dilatation or cutting balloon with or without stenting or by endovascular laser. This intervention happens only once; the duration of the intervention depends on the procedure and the original injuries(30 - 120 minutes).

Eligibility Criteria:
Inclusion Criteria:

* Diabetes type I or II with diabetic angiopathy stage IIb to IV (Fontaine)
* Atherosclerotic patients with distal angiopathy stage IIb to IV (Fontaine)

Exclusion Criteria:

* Acute ischemia
* Multisegmentaric damage above the knee
* Sepsis: acute respiratory distress syndrome (ARDS), C-reactive protein (CRP) \> 30, white blood cell (WBC) \> 25,000
* Acute myocardial infarction (AMI) during the last 14 days
* Operative contraindication
* Life expectancy \< 2 years
* Blue toe syndrome (micro-embolisation)
Outcomes of Bipolar Electrocautery Tonsillectomy Versus Cold Steel Dissection Pediatric Tonsillectomy

It was intended to practically establish whether or not the relatively newer technique of tonsillectomy like bipolar electrocautery tonsillectomy has any added benefits in reducing the duration of surgery, blood loss and post-operative pain as compared with conventional cold steel dissection method. This study was done to compare the outcomes of bipolar electrocautery tonsillectomy versus cold steel dissection pediatric tonsillectomy.


Eligibility Criteria:
Inclusion Criteria:

* Patients of 5-13 years of age
* Both genders
* With a history of recurrent episodes of tonsillitis in the last year
* Children who had bilaterally enlarged tonsils
* No history of fever or sore throat in the last 4 weeks

Exclusion Criteria:

* Patients who had enlarged adenoids and required adenotonsillectomy
* Patients who underwent tonsillectomy after quinsy
* With a history of bleeding disorders
* Patients who showed an international normalized ratio (INR) ≥ 1.5
Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)

This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine granules vs. once daily 1.5 g mesalazine granules vs. three times daily 0.5 g mesalazine granules for maintenance of remission in patients with ulcerative colitis


Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent,
* Men or women aged 18 to 75 years,
* Historically confirmed diagnosis of ulcerative colitis by endoscopy and histology,
* Patient being in remission, defined (according to Rachmilewitz) as:

Clinical Activity Index (CAI) \<= 4, and Endoscopic Index (EI) \< 4,

* Extent of inflammation during last acute episode was \>15 cm beyond the anal margin,
* Last acute episode ended within 3 months prior to study entry.

Exclusion Criteria:

* Crohn's disease,
* Prior bowel resection leading to diarrhoea,
* Toxic megacolon,
* Gastric or duodenal ulcer,
* Haemorrhagic diathesis,
* Presence of symptomatic organic disease of the gastrointestinal tract (with the exception of haemorrhoids or hiatal hernia),
* Active colorectal cancer or a history of colorectal cancer,
* Serious other secondary illnesses of an acute or chronic nature,
* Asthma,
* Severe impairment of renal (e.g., serum creatinine \> 1.5 mg/dl) and/or liver functions (e.g., serum transaminase \[ALT and/or AST\] or alkaline phosphatase \>=2x upper limit of normal \[ULN\]),
* Application of immunosuppressants within 3 months and/or corticosteroids (oral, intravenous \[IV\] or topical rectal) within 30 days prior to baseline,
* Application of non-steroidal anti-inflammatory drugs (NSAIDs) as long term treatment (i.e. \> 6 weeks), other than acetylsalicylic acid (\<= 350 mg/day), or paracetamol,
* Known intolerance/hypersensitivity to salicylic acid and its derivatives or to any of the other constituents of the study drugs,
* Well-founded doubt about the patient's cooperation,
* Existing or intended pregnancy, breast-feeding,
* Women of child-bearing potential without adequate contraceptive protection, e.g., hormonal contraception, intrauterine device (IUD), double-barrier method of contraception (e.g., use of a condom and spermicide), partner has undergone vasectomy and subject is in monogamous relationship. The investigator is responsible for determining whether the subject has adequate birth control for study participation,
* Participation in another clinical trial within the last 30 days,simultaneous participation in another clinical trial, or previous participation in this trial.
Screening for Familial Hypercholesterolemia in Children

Familial hypercholesterolemia is the most common treatable genetic disorder for which a simple, effective treatment is available, with few side effects.

It leads to a significant increase in LDL levels, generally in excess of 1.9g/l, including in children. It is much higher than the values usually found in secondary or polygenic hypercholesterolemia. This condition multiplies the cardiovascular risk in adulthood by a factor of 13, and is responsible for 6,500 early cardiovascular events per year. In the absence of treatment, the state of the arteries of patients with familial hypercholesterolemia, at the age of 40, would be equivalent to that of 80-year-olds.

Currently, the prevalence is estimated at 1 in 300 people in France. However, this prevalence is largely underestimated, as targeted screening is rarely carried out, and it is estimated that only 10% of sufferers are diagnosed in France, and only 5% of affected children are known and treated.

Today, according to the French health authority, the indications for screening children are: a history of an early vascular event in one of the two parents, or familial hypercholesterolemia in a first-degree relative.

However, the World Health Organization and numerous studies recommend extending screening to the general population. Screening all children and teenagers could make it possible to introduce healthy dietary habits at an early stage, to better adapt the choice of contraception in young women, to treat before the first symptoms appear and thus reduce mortality in adulthood by up to 48%, and to screen relatives who have not yet had a cardiovascular event.

In Slovenia, 90% of children have had a lipid panel since 1994, significantly reducing mortality. In the United Kingdom, the lipid check-up, offered as part of a compulsory visit at the age of two, is being rolled out: 90% of families naturally take it up on the recommendation of their doctors.

The treatment of hypercholesterolemia is simple, and relies first and foremost on hygienic dietary rules and treatments such as statins and Liptruzet (a combination of atorvastatin and ezetimibe), treatments that are easily accessible, effective, with few side effects and low cost.


Eligibility Criteria:
Inclusion Criteria:

* Age between 2 and 18 years
* Minimum 8-hour fasting
* Parents and children with signed informed consent

Exclusion Criteria:

* Known familial hypercholesterolemia
* Diabetes less than one month old
* Profound hypothyroidism
* Acute nephrotic syndrome
* cancer under treatment
Magnetic Resonance Imaging to Study the Normal Eye

This study will assess the value of improved magnetic resonance imaging (MRI) techniques to study the lens of the human eye. Knowledge of how cataracts develop and progress has been hampered by the lack of human tissue available for study; MRI may provide an effective means for learning more about this eye disease.

Normal volunteers between 18 and 70 years of age may be eligible for this study. Participants will undergo a medical history and complete eye examination, including vision assessment, eye pressure measurement, lens and retina examinations, and photography of the eye.

MRI scans will be scheduled for a second visit. For this procedure, the volunteer's pupils are dilated and he or she then lies on a stretcher that is moved into a cylinder containing a magnetic field. A device similar to a welder's helmet is placed on the head. Attached to the device are an imaging probe and a small blinking light. The probe receives radio signals from the eye that a computer converts into images. During imaging, the participant gazes at the blinking light; this helps keep the eyes from blinking and wandering. Scan times vary from 2 to 10 minutes; the total time for the study is less than an hour.

Studies of human diabetic cataract and age related cataract formation have been hampered by unavailability of human tissues especially in the early stages of the disease. Eye bank tissues are first used for cornea transplants so that by the time they become available for basic research studies, the lens is no longer suitable for biochemical nor histological studies. Cataracts usually only become available after extraction which is at the end stage of their development. However, appropriate surgical lens specimens are no longer available because cataracts are generally extracted by the destructive phakoemulsification technique. Therefore, noninvasive techniques are required in order to study the lens in vivo.

Eligibility Criteria:
Must be between 18 and 70 years of age of either sex.

Must not have uveitis, glaucoma, or be at risk for an adverse reaction to dilation or have a history of allergic reaction to one of lthe dilating agents to be used.

Must not have any metallic prosthesis, cardiac pacemakers, neural pacemakers, surgical clips in the brain or on blood vessels, surgically implanted metal plates, screws or pins, cochlear implants or metal objects in the body especially in the eye.